Supplementary material: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023

Name: Supplementary material: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023
Creator: Xiaoling Wei
Published: 2023-08-04T12:00:04.930Z
Keywords: Dermatology

Wei, Xiaoling; Passera, Anna; Muscianisi , Elisa; Uhlmann , Lorenz; Chen, Li; Moreno , Santiago G.; Martin, Ruvie; Vandemeulebroecke , Marc; Keefe, Deborah; Ravichandran, Shoba; Wozniak, Magdalena

doi:10.17632/dw5fk5y4j9.1

Supplementary material: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023

Published: 4 August 2023| Version 1 | DOI: 10.17632/dw5fk5y4j9.1

Contributors:

Xiaoling Wei, Anna Passera, Elisa Muscianisi , Lorenz Uhlmann , Li Chen, Santiago G. Moreno , Ruvie Martin, Marc Vandemeulebroecke , Deborah Keefe, Shoba Ravichandran, Magdalena Wozniak

Description

Supplemental text and table for: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023

Supplementary material: Wei et al. Assessing the validity and clinical meaningfulness of skin pain response (NRS30) assessed using numerical rating scale in hidradenitis suppurativa: Results from the SUNSHINE and SUNRISE trials. JAAD 2023

Description

Files

Institutions

Categories

Funding

Licence